Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ.

Clin Pharmacol Ther. 2009 Jul;86(1):97-100. doi: 10.1038/clpt.2009.68. Epub 2009 May 13.

PMID:
19440188
2.

Neoadjuvant trials could speed up drug approvals.

Peres J.

J Natl Cancer Inst. 2014 Mar;106(3):dju072. doi: 10.1093/jnci/dju072. Epub 2014 Mar 7. No abstract available.

PMID:
24610911
3.

Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting.

Kalinsky K, Hershman DL.

J Comp Eff Res. 2013 Jul;2(4):393-403. doi: 10.2217/cer.13.35.

4.

Adaptive trials receive boost.

Jones D.

Nat Rev Drug Discov. 2010 May;9(5):345-8. doi: 10.1038/nrd3174. Epub 2010 Apr 23. No abstract available.

PMID:
20414200
5.

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.

Generali D, Berruti A, Foroni C, Bazzola L, Andreis D, Allevi G, Bersiga A, Dogliotti L, Fox SB, Harris AL, Bottini A.

J Natl Cancer Inst Monogr. 2011;2011(43):67-70. doi: 10.1093/jncimonographs/lgr029.

PMID:
22043044
6.

Neoadjuvant chemotherapy and targeted therapies: a promising strategy.

Metzger-Filho O, de Azambuja E.

J Natl Cancer Inst Monogr. 2011;2011(43):116-9. doi: 10.1093/jncimonographs/lgr019.

PMID:
22043056
7.

New agent development for women with breast cancer.

Von Hoff DD.

Cancer Invest. 1995;13(3):341-4. No abstract available.

PMID:
7743387
8.

Neoadjuvant therapy as a platform for drug development and approval in breast cancer.

Bardia A, Baselga J.

Clin Cancer Res. 2013 Dec 1;19(23):6360-70. doi: 10.1158/1078-0432.CCR-13-0916. Review.

9.

Neoadjuvant breast cancer therapy and drug development.

Cortazar P, Kluetz PG.

Clin Adv Hematol Oncol. 2015 Nov;13(11):755-61. Review.

PMID:
27058702
10.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25.

11.

Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?

Generali D, Ardine M, Strina C, Milani M, Cappelletti MR, Zanotti L, Forti M, Bedussi F, Martinotti M, Amoroso V, Sigala S, Simoncini E, Berruti A, Bottini A.

J Natl Cancer Inst Monogr. 2015 May;2015(51):32-5. doi: 10.1093/jncimonographs/lgv019.

PMID:
26063883
12.

Adaptive design may hasten clinical trials.

Schmidt C.

J Natl Cancer Inst. 2007 Jan 17;99(2):108-9. No abstract available.

PMID:
17227993
13.

The clinical trials of the Organisation for Oncology and Translational Research (OOTR).

Chow LW, Toi M.

Int J Biol Markers. 2012 Dec 27;27(4):e353-6. doi: 10.5301/JBM.2012.10371.

PMID:
23250776
14.
15.

Developing safety criteria for introducing new agents into neoadjuvant trials.

DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L.

Clin Cancer Res. 2013 Jun 1;19(11):2817-23. doi: 10.1158/1078-0432.CCR-12-2620. Epub 2013 Mar 7. Review.

16.

Is there still a role for neoadjuvant therapy in breast cancer?

Shannon C, Smith I.

Crit Rev Oncol Hematol. 2003 Jan;45(1):77-90. Review.

PMID:
12482573
17.

Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer.

Garg AK, Buchholz TA.

Ann Surg Oncol. 2015 May;22(5):1434-40. doi: 10.1245/s10434-015-4402-x. Epub 2015 Mar 2. Review.

PMID:
25727554
18.

Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).

Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ.

Ann Surg Oncol. 2014 Sep;21(9):2889-96. doi: 10.1245/s10434-014-3721-7. Epub 2014 May 1.

19.

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M; BIG-NABCG collaboration.

Lancet Oncol. 2012 Jun;13(6):e240-8. doi: 10.1016/S1470-2045(11)70378-3.

PMID:
22652232
20.

Avastin saga reveals debate over clinical trial endpoints.

Sharma SP.

J Natl Cancer Inst. 2012 Jun 6;104(11):800-1. doi: 10.1093/jnci/djs265. Epub 2012 Jun 6. No abstract available.

PMID:
22673590

Supplemental Content

Support Center